drugset / Trial / NCT01104935

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]

NCT01104935

RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate clinical positioning between trastuzumab (Herceptin) monotherapy (H group) and combination therapy of trastuzumab and chemotherapy (H+CT group) based on a randomized controlled trial in women over 70 years with human epidermal growth factor receptor type-2 (HER2) positive primary breast cancer.

Timeline

Start
2009-10-28
Primary completion
2017-10-31
Completion
2018-10-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous

Indications